Tag Archives: Partnership

August 17, 2022
FeaturedPress Release

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]

Read Article
December 18, 2020
In The News

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents.

Read Article
December 18, 2020
FeaturedPress Release

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December  18, 2020 – Atomwise, the leader in using artificial […]

Read Article
October 6, 2020
In The News

Atomwise announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies.

Read Article
October 6, 2020
FeaturedPress Release

The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network SAN FRANCISCO, CA — October 6th, 2020 — Atomwise, the leader in using artificial intelligence (AI) for small […]

Read Article
September 23, 2020
In The News

[Hemophilia News Today] Atomwise, a company that specializes in using artificial intelligence (AI) to develop small molecule medicines, will partner with GC Pharma to discover new ways of treating people with hemophilia. 

Read Article